尿路上皮がん治療薬の世界市場レポート 2025年

尿路上皮がん治療薬の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR20.0％で70億4,000万米ドルに成長します。予測期間の成長は、画像診断の進歩、薬剤開発における人工知能、患者中心のケア、研究開発への投資、規制の変更などに起因すると考えられます。予測期間における主な動向は、画像技術の進歩、患者中心のケア、ヘルスケア償還、ゲノムプロファイリング、規制枠組みなどです。

尿路上皮がんの有病率の増加は、将来の尿路上皮がん治療薬市場を押し上げると予想されます。尿路上皮がんは、尿道、膀胱、尿管、腎盂を含む様々な臓器を覆う尿路上皮細胞を含みます。尿路上皮がんの罹患率の増加により、この疾患を治療し死亡率を低下させるための新薬や治療法の開発が必要となっています。例えば、2023年1月、米国の任意団体である米国がん協会（American Cancer Society Inc.）は、合計8万2,290人の新規症例のうち、男性約6万2,420人、女性約1万9,870人が膀胱がんと診断されたと報告しました。さらに、膀胱がんに起因する死亡者は1万6,710人で、その内訳は女性4,550人、男性1万2,160人でした。したがって、尿路上皮がんの有病率の上昇は、尿路上皮がん治療薬市場の成長を促進すると予想されます。

化学療法に対する需要の増加は、尿路上皮がん治療薬市場の成長を促進します。化学療法は、血流を介して全身を循環する全身治療であり、遠隔部位に転移した可能性のあるがん細胞に対して有効であることが証明されています。尿路上皮がん管理における化学療法の適用には、がん細胞の増殖抑制、転移性疾患の治療、急速に分裂する細胞の標的化、症状緩和と患者のQOL向上のための緩和ケアなどが含まれます。ヘルスケアITニュースが2022年2月に報じたように、国際がん対策連合（UICC）によると、がん化学療法の需要は2040年までに1,000万人から1,500万人に増加すると予想されています。化学療法の需要増加は、尿路上皮がん治療におけるその重要な役割を示し、尿路上皮がん治療薬市場の成長に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の尿路上皮がん治療薬市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の尿路上皮がん治療薬市場：成長率分析
• 世界の尿路上皮がん治療薬市場の実績：規模と成長、2019～2024年
• 世界の尿路上皮がん治療薬市場の予測：規模と成長、2024～2029年、2034年
• 世界の尿路上皮がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の尿路上皮がん治療薬市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 尿路上皮がん
• 扁平上皮がん
• 腺がん
• 世界の尿路上皮がん治療薬市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫療法
• 化学療法
• 保存療法
• 世界の尿路上皮がん治療薬市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 専門クリニック
• がん研究所
• 外来手術センター
• 世界の尿路上皮がん治療薬市場：尿路上皮がんのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法剤
• 免疫療法剤
• 標的治療薬
• 世界の尿路上皮がん治療薬市場：扁平上皮がんのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法剤
• 免疫療法剤
• 標的治療薬
• 世界の尿路上皮がん治療薬市場：腺がんのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 化学療法剤
• 免疫療法剤
• 標的治療薬

第7章 地域別・国別分析

• 世界の尿路上皮がん治療薬市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の尿路上皮がん治療薬市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿路上皮がん治療薬市場：競合情勢
• 尿路上皮がん治療薬市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK PLC
• UroGen Pharma Inc.
• Johnson & Johnson Inc.
• Astellas Pharma Inc.
• Sesen Bio Inc.
• Seagen Inc.
• Eisai Co. Ltd.
• Agensys Inc.
• AstraZeneca
• Novartis AG
• GlaxoSmithKline PLC
• Sanofi SA
• Janssen Pharmaceuticals Inc.
• Seattle Genetics Inc.
• AbbVie Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 尿路上皮がん治療薬市場2029年：新たな機会を提供する国
• 尿路上皮がん治療薬市場2029年：新たな機会を提供するセグメント
• 尿路上皮がん治療薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urothelial cancer drugs encompass medications and therapies designed to target and treat cancer associated with urothelial cells lining the urethra, bladder, ureters, and renal pelvis. These treatments aim to eliminate cancerous cells and offer non-vesical chemotherapy options. They are primarily utilized for both prevention and treatment of urothelial cancer.

The main types of urothelial cancer include urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma. Urothelial carcinoma specifically addresses epithelial tissue tumors, referring to transitional cell cancer occurring near epithelial tissues. Urothelial cancer drugs typically encompass treatment approaches such as immunotherapy, chemotherapy, and preservation therapy, all tailored for managing urothelial cancer. These drugs are distributed through various channels including hospital pharmacies, specialty clinics, cancer institutes, and ambulatory surgical centers.

The urothelial cancer drugs market research report is one of a series of new reports from The Business Research Company that provides urothelial cancer drugs market statistics, including urothelial cancer drugs industry global market size, regional shares, competitors with a urothelial cancer drugs market share, detailed urothelial cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the urothelial cancer drugs industry. This urothelial cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial cancer drugs market size has grown exponentially in recent years. It will grow from $2.81 billion in 2024 to $3.4 billion in 2025 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to awareness and early detection initiatives, physician education and training, patient advocacy groups, evolving standard of care, biomarker identification.

The urothelial cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $7.04 billion in 2029 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to advancements in diagnostic imaging, artificial intelligence in drug development, patient-centric care, investment in research & development, regulatory changes. Major trends in the forecast period include advances in imaging technologies, patient-centric care, healthcare reimbursement, genomic profiling, regulatory frameworks.

The increasing prevalence of urothelial cancer is anticipated to boost the urothelial cancer drug market in the future. Urothelial cancer involves the urothelial cells that line various organs, including the urethra, bladder, ureters, and renal pelvis. The growing incidence of urothelial cancer necessitates the development of new drugs and therapies to treat this condition and reduce mortality rates. For example, in January 2023, the American Cancer Society Inc., a US-based voluntary health organization, reported that approximately 62,420 men and 19,870 women were diagnosed with bladder cancer, out of a total of 82,290 new cases. Additionally, there were 16,710 deaths attributed to bladder cancer, comprising 4,550 women and 12,160 men. Therefore, the rising prevalence of urothelial cancer is expected to drive the growth of the urothelial cancer drug market.

The increasing demand for chemotherapy is set to propel the growth of the urothelial cancer drugs market. Chemotherapy, a systemic treatment circulating throughout the body via the bloodstream, proves effective against cancer cells that may have spread to distant sites. Its application in urothelial cancer management includes inhibiting cancer cell growth, treating metastatic disease, targeting rapidly dividing cells, and providing palliative care to relieve symptoms and improve patients' quality of life. As reported in February 2022 by Healthcare IT News, the demand for cancer chemotherapy is expected to rise from 10 million to 15 million by 2040, according to the Union for International Cancer Control (UICC). The increasing demand for chemotherapy underscores its crucial role in urothelial cancer treatment, contributing to the growth of the urothelial cancer drugs market.

The rising prevalence of the geriatric population is contributing to the growth of the urothelial cancer drugs market. Individuals aged 65 and older are classified as part of the geriatric population. Due to weakened immunity and advanced age, older adults are more vulnerable to various diseases. The risk of urothelial cancer increases with age, which creates a demand for urothelial cancer drugs to treat this population. For example, in October 2022, the World Health Organization, a US-based specialized health agency, projected that globally, 1 in 6 people will be 60 or older by 2030, with the number of individuals in this age group expected to double to 2.1 billion by 2050. Furthermore, according to data published by the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase, with this age group's share of the total population rising from 17% to 23%. Therefore, the increasing prevalence of the geriatric population is set to drive the urothelial cancer drugs market.

Novel combination therapies are emerging as a significant trend in the urothelial cancer drug market. Combination therapy involves the use of two or more therapeutic agents for treatment. Key players are focusing on developing combination therapies to maintain their position in the urothelial cancer drug market. The integration of immunotherapy with targeted drugs offers a promising approach to mitigate the development of resistance and enhance response in cancer management. For example, in July 2022, the United States Food and Drug Administration (FDA), a federal agency within the Department of Health and Human Services, approved the biologics license application (BLA) for ImmunityBio's N-803, an IL-15 superagonist, in combination with the Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer. This marks the first immunotherapy combination that can be administered directly to stimulate natural killer cells and T cells within the bladder.

Prominent companies in the urothelial cancer drugs market are prioritizing product approvals, such as Padcev in combination with Keytruda, to enhance revenues in the market. The Padcev-Keytruda combination represents a therapeutic option for treating urothelial cancer. For instance, in April 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Padcev with Keytruda. This combination therapy is indicated for metastatic urothelial cancer. When cisplatin-containing chemotherapy is unsuitable for certain patients with locally advanced or metastatic urothelial carcinoma, the Padcev and pembrolizumab combination is recommended as the initial line of treatment. In patients with advanced bladder cancer, the Padcev-Keytruda combination has shown a significant improvement in overall survival and progression-free survival rates.

Major companies operating in the urothelial cancer drugs market are F Hoffmann La Roche AG, The Bristol-Myers Squibb Company, Merck & Co Inc., Pfizer Inc., Genentech Inc., GSK PLC, UroGen Pharma Inc., Johnson & Johnson Inc., Astellas Pharma Inc., Sesen Bio Inc., Seagen Inc., Eisai Co. Ltd., Agensys Inc., AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Sanofi SA, Janssen Pharmaceuticals Inc., Seattle Genetics Inc., AbbVie Inc., Millennium Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Spectrum Pharmaceuticals Inc., Zydus Lifesciences Ltd.

North America was the largest region in the urothelial cancer drugs market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the urothelial cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urothelial cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urothelial cancer drugs market consists of sales of targeted therapy urothelial cancer drugs and chemo therapy urothelial cancer drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urothelial Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urothelial cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urothelial cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urothelial cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Urothelial Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma
• 2) By Treatment: Immunotherapy; Chemotherapy; Preservation Therapy
• 3) By Distribution Channel: Hospital Pharmacies; Specialty Clinics; Cancer Institutes; Ambulatory Surgical Centers
• Subsegments:
• 1) By Urothelial Carcinoma: Chemotherapy Agents; Immunotherapy Agents; Targeted Therapy Drugs
• 2) By Squamous Cell Carcinoma: Chemotherapy Agents; Immunotherapy Agents; Targeted Therapy Drugs
• 3) By Adenocarcinoma: Chemotherapy Agents; Immunotherapy Agents; Targeted Therapy Drugs
• Companies Mentioned: F Hoffmann La Roche AG; The Bristol-Myers Squibb Company; Merck & Co Inc.; Pfizer Inc.; Genentech Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urothelial Cancer Drugs Market Characteristics

3. Urothelial Cancer Drugs Market Trends And Strategies

4. Urothelial Cancer Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Urothelial Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urothelial Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urothelial Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Urothelial Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urothelial Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urothelial Cancer Drugs Total Addressable Market (TAM)

6. Urothelial Cancer Drugs Market Segmentation

• 6.1. Global Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urothelial Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma
• 6.2. Global Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Chemotherapy
• Preservation Therapy
• 6.3. Global Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Specialty Clinics
• Cancer Institutes
• Ambulatory Surgical Centers
• 6.4. Global Urothelial Cancer Drugs Market, Sub-Segmentation Of Urothelial Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Immunotherapy Agents
• Targeted Therapy Drugs
• 6.5. Global Urothelial Cancer Drugs Market, Sub-Segmentation Of Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Immunotherapy Agents
• Targeted Therapy Drugs
• 6.6. Global Urothelial Cancer Drugs Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Immunotherapy Agents
• Targeted Therapy Drugs

7. Urothelial Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Urothelial Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urothelial Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urothelial Cancer Drugs Market

• 8.1. Asia-Pacific Urothelial Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urothelial Cancer Drugs Market

• 9.1. China Urothelial Cancer Drugs Market Overview
• 9.2. China Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urothelial Cancer Drugs Market

• 10.1. India Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urothelial Cancer Drugs Market

• 11.1. Japan Urothelial Cancer Drugs Market Overview
• 11.2. Japan Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urothelial Cancer Drugs Market

• 12.1. Australia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urothelial Cancer Drugs Market

• 13.1. Indonesia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urothelial Cancer Drugs Market

• 14.1. South Korea Urothelial Cancer Drugs Market Overview
• 14.2. South Korea Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urothelial Cancer Drugs Market

• 15.1. Western Europe Urothelial Cancer Drugs Market Overview
• 15.2. Western Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urothelial Cancer Drugs Market

• 16.1. UK Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urothelial Cancer Drugs Market

• 17.1. Germany Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urothelial Cancer Drugs Market

• 18.1. France Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urothelial Cancer Drugs Market

• 19.1. Italy Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urothelial Cancer Drugs Market

• 20.1. Spain Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urothelial Cancer Drugs Market

• 21.1. Eastern Europe Urothelial Cancer Drugs Market Overview
• 21.2. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urothelial Cancer Drugs Market

• 22.1. Russia Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urothelial Cancer Drugs Market

• 23.1. North America Urothelial Cancer Drugs Market Overview
• 23.2. North America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urothelial Cancer Drugs Market

• 24.1. USA Urothelial Cancer Drugs Market Overview
• 24.2. USA Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urothelial Cancer Drugs Market

• 25.1. Canada Urothelial Cancer Drugs Market Overview
• 25.2. Canada Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urothelial Cancer Drugs Market

• 26.1. South America Urothelial Cancer Drugs Market Overview
• 26.2. South America Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urothelial Cancer Drugs Market

• 27.1. Brazil Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urothelial Cancer Drugs Market

• 28.1. Middle East Urothelial Cancer Drugs Market Overview
• 28.2. Middle East Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urothelial Cancer Drugs Market

• 29.1. Africa Urothelial Cancer Drugs Market Overview
• 29.2. Africa Urothelial Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urothelial Cancer Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urothelial Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urothelial Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Urothelial Cancer Drugs Market Competitive Landscape
• 30.2. Urothelial Cancer Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Genentech Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Urothelial Cancer Drugs Market Other Major And Innovative Companies

• 31.1. GSK PLC
• 31.2. UroGen Pharma Inc.
• 31.3. Johnson & Johnson Inc.
• 31.4. Astellas Pharma Inc.
• 31.5. Sesen Bio Inc.
• 31.6. Seagen Inc.
• 31.7. Eisai Co. Ltd.
• 31.8. Agensys Inc.
• 31.9. AstraZeneca
• 31.10. Novartis AG
• 31.11. GlaxoSmithKline PLC
• 31.12. Sanofi SA
• 31.13. Janssen Pharmaceuticals Inc.
• 31.14. Seattle Genetics Inc.
• 31.15. AbbVie Inc.

32. Global Urothelial Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urothelial Cancer Drugs Market

34. Recent Developments In The Urothelial Cancer Drugs Market

35. Urothelial Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Urothelial Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urothelial Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urothelial Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer